secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K/A
Filed at:   2023-10-17T23:59:59+00:00
Accession:  0001737287-23-000083
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Allogene appoints Geoffrey Parker as CFO with $490K salary and equity grants
----------------------------------------------------------------------------

- Geoffrey Parker appointed EVP, CFO, Principal Financial and Accounting Officer effective Oct 16, 2023.
- Replaces David Chang and Jack Chen as interim principal financial and accounting officers.
- Prior roles: COO/CFO of Tricida, CFO of Anacor (acquired by Pfizer for $5.2B), MD at Goldman Sachs.
- Compensation: $490K base salary, 45% target bonus, stock option for 950K shares, RSU for 400K shares.
- Performance RSU of 390K shares vests upon $18.00 share price or first FDA product approval by 2026/2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/0001737287-23-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000083/allo-20231016.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer